Levocetirizine 5 mg
Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-
receptors. Binding studies revealed that levocetirizine has high affinity for human H1- receptors .
Levocetirizine has an affinity 2-fold higher than that of cetirizine. Levocetirizine diSsociates from H1-receptors
with a half-life of 115 ± 38 min. At half the dose, levocetirizine has comparable activity to cetirizine, both in the
skin and in the nose. In vitro studies show that levocetirizine inhibits eosinophil transendothelial migration
through both dermal and lung cells. A pharmacodynamic experimental study in vivo (skin chamber
technique) showed three main inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced
reaction, compared with placebo : inhibition of VCAM-1 release, modulation of vascular permeability and a
decrease in eosinophil recruitment. Levocetirizine is rapidly and extensively.
Levocetirizine is indicated in the treatment of perennial and seasonal allergic rhinitis and chronic idiopathic
DOSAGE AND ADMINISTRATION
Adults & Children (aged above 6 years):
One tablet, 5 mg daily
The tablet should be swallowed whole with liquid and may be taken with or without meals.